v3.25.2
ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Schedule of Consideration for Mirati Acquisition (Details) - Mirati Therapeutics - USD ($)
$ in Millions
6 Months Ended
Jan. 23, 2024
Jun. 30, 2024
Business Combination [Line Items]    
Total consideration $ 4,801  
Plus: Fair value of CVRs 248  
Total consideration allocated 4,935  
Common Stock    
Business Combination [Line Items]    
Total consideration 4,596  
Equity    
Business Combination [Line Items]    
Total consideration 205  
Unvested Equity Awards    
Business Combination [Line Items]    
Less: unvested stock awards $ (114)  
Unvested Equity Awards | Selling, general and administrative    
Business Combination [Line Items]    
Total consideration   $ 60
Unvested Equity Awards | Research and development    
Business Combination [Line Items]    
Total consideration   $ 54